BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18434637)

  • 1. Selection of response criteria for clinical trials of sarcoma treatment.
    Schuetze SM; Baker LH; Benjamin RS; Canetta R
    Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective.
    Benjamin RS
    Oncologist; 2008; 13 Suppl 2():1-3. PubMed ID: 18434630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R; Llovet JM
    Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response assessment in clinical trials: implications for sarcoma clinical trial design.
    Jaffe CC
    Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Other endpoints in screening studies for soft tissue sarcomas.
    Verweij J
    Oncologist; 2008; 13 Suppl 2():27-31. PubMed ID: 18434636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
    Mazumdar M; Smith A; Schwartz LH
    J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.
    Schmitt T; Kasper B
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1159-67. PubMed ID: 19671035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. We should desist using RECIST, at least in GIST.
    Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
    J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RECIST revisited: a review of validation studies on tumour assessment.
    Therasse P; Eisenhauer EA; Verweij J
    Eur J Cancer; 2006 May; 42(8):1031-9. PubMed ID: 16616487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
    Roedl JB; Colen RR; Holalkere NS; Fischman AJ; Choi NC; Blake MA
    Radiother Oncol; 2008 Dec; 89(3):278-86. PubMed ID: 18701180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.
    Stacchiotti S; Collini P; Messina A; Morosi C; Barisella M; Bertulli R; Piovesan C; Dileo P; Torri V; Gronchi A; Casali PG
    Radiology; 2009 May; 251(2):447-56. PubMed ID: 19261927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of adult soft tissue sarcomas.
    Mendenhall WM; Indelicato DJ; Scarborough MT; Zlotecki RA; Gibbs CP; Mendenhall NP; Mendenhall CM; Enneking WF
    Am J Clin Oncol; 2009 Aug; 32(4):436-42. PubMed ID: 19657238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Measurement of tumour response to cancer treatment: morphologic imaging role].
    Ollivier L; Leclère J; Thiesse P; Di Stefano D; Vincent C
    Bull Cancer; 2007 Feb; 94(2):171-7. PubMed ID: 17337386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay.
    Tewfik JN; Greene GS
    Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologic measurements of tumor response to treatment: practical approaches and limitations.
    Suzuki C; Jacobsson H; Hatschek T; Torkzad MR; Bodén K; Eriksson-Alm Y; Berg E; Fujii H; Kubo A; Blomqvist L
    Radiographics; 2008; 28(2):329-44. PubMed ID: 18349443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New guidelines to evaluate the response to treatment "RECIST"].
    Sasaki T
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2179-84. PubMed ID: 11142160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    Stahl R; Wang T; Lindner LH; Abdel-Rahman S; Santl M; Reiser MF; Issels RD
    Int J Hyperthermia; 2009 Jun; 25(4):289-98. PubMed ID: 19670096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.